BeOne Medicines (ONC) Retained Earnings (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Retained Earnings data on file, last reported at $12.9 billion in Q1 2026.

• On a quarterly basis, Retained Earnings rose 5.38% year-over-year to $12.9 billion in Q1 2026; TTM through Mar 2026 was $12.9 billion, a 5.38% increase from a year earlier, with the FY2025 full-year figure at -$8.3 billion, down 168.83% from the prior year.
• Retained Earnings for Q1 2026 stood at $12.9 billion, up from -$8.3 billion in the prior quarter.
• Over the last five years, Retained Earnings for ONC reached as high as $12.9 billion in Q1 2026 and fell as low as -$8.5 billion in Q2 2025.
• Historically, Retained Earnings has averaged $6.4 billion across 5 years, with a median of $11.5 billion in 2022.
• Across the five-year window, Retained Earnings sank 781.69% in 2022 and jumped 14353.51% in 2023, its largest moves.
• Year by year, Retained Earnings stood at $11.5 billion in 2022, then increased by 0.5% to $11.6 billion in 2023, then climbed by 4.22% to $12.1 billion in 2024, then tumbled by 168.83% to -$8.3 billion in 2025, then surged by 255.13% to $12.9 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $12.9 billion in Q1 2026, -$8.3 billion in Q4 2025, and $12.6 billion in Q3 2025.